Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/01/17 03:28:11」(JST)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives.

Imamura Y, Shinozaki T, Okada-Ogawa A, Noma N, Shinoda M, Iwata K, Wada A, Abe O, Wang K, Svensson P.
Journal of oral rehabilitation. 2019 Jun;46(6)574-587.
Burning mouth syndrome (BMS) is a chronic oro-facial pain disorder of unknown cause. It is more common in peri- and post-menopausal women, and sex hormone dysregulation is believed to be an important causative factor. Psychosocial events often trigger or exacerbate symptoms, and persons with BMS app
PMID 30892737

Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, Shen YL, Sheth CM, Liu C, Leong R, Goldberg KB, Farrell AT, Pazdur R.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May;().
On November 21, 2018, the Food and Drug Administration approved glasdegib (Daurismo; Pfizer, New York, NY), a small molecule Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC) for treatment of newly-diagnosed acute myeloid leukemia (AML) in adults ≥ 75 years or with comorbidities t
PMID 31064779

Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects.

Bánvölgyi A, Anker P, Lőrincz K, Kiss N, Márton D, Fésűs L, Gyöngyösi N, Wikonkál N.
The Journal of dermatological treatment. 2019 May;()1-12.
Smoothened receptor inhibitor vismodegib is indicated to treat locally advanced basal cell carcinoma (laBCC) and lesions in nevoid basal cell carcinoma syndrome (NBCCS). We treated 11 patients - including four NBCCS and seven laBCC patients - with vismodegib at our department. Complete remission was
PMID 31039644